Myocilin Gene Gln368Ter Variant Penetrance and Association With Glaucoma in Population-Based and Registry-Based Studies

Xikun Han, MSc; Emmanuelle Souzeau, PhD; Jue-Sheng Ong, MSc; Jiyuan An, PhD; Owen M. Siggs, MD, DPhil; Kathryn P. Burdon, PhD; Stephen Best, MBChB, FRANZCO; Ivan Goldberg, MBBS FRANZCO; Paul R. Healey, PhD, FRANZCO; Stuart L. Graham, PhD, FRANZCO; Jonathan B. Ruddle, MBBS, FRANZCO; Richard A. Mills, PhD, FRANZCO; John Landers, PhD, FRANZCO; Anna Galanopoulos, MBBS, FRANZCO; Andrew J.R. White, PhD, FRANZCO; Robert Casson, DPhil, FRANZCO; David A. Mackey, MD, FRANZCO; Alex W. Hewitt, MBBS, PhD; Puya Gharahkhani, PhD; Jamie E. Craig, DPhil, FRANZCO; Stuart MacGregor, PhD

IMPORTANCE The p.Gln368Ter (rs74315329) risk allele in the myocilin gene (MYOC) was initially reported to have high penetrance in glaucoma registry-based studies, but much lower estimates were recently obtained from population-based studies. We investigated this disparity using data from Australia and the United Kingdom.

OBJECTIVES To examine the penetrance and effect size of the MYOC p.Gln368Ter variant with glaucoma and ocular hypertension (OHT).

DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study within the UK Biobank (UKBB) included participants of white British ancestry. Glaucous cases were defined by International Classification of Diseases, Ninth Revision (ICD-9) and Tenth Revision (ICD-10) diagnoses and self-reported questionnaires. Carriers of the MYOC p.Gln368Ter variant were identified using genotype imputation from arrays. In contrast, 2 Australian registry-based studies, the Australian and New Zealand Registry of Advanced Glaucoma and the Glaucoma Inheritance Study in Tasmania, ascertained glaucoma cases referred by eye care clinicians, with historic control participants recruited from other Australian studies. Samples were either directly sequenced or had genotypes determined by imputation (for the Australian registry and historic control participants). Recruitment to the UKBB occurred between 2006 and 2010, and data analysis occurred from September 2017 to July 2018.

MAIN OUTCOMES AND MEASURES The penetrance and odds ratio (OR) were estimated for the MYOC p.Gln368Ter variants in participants with glaucoma and OHT.

RESULTS A total of 411,337 UKBB participants of white British ancestry (mean [SD] age, 56.6 [8.0] years) were included, plus 3071 Australian registry and 6750 historic control participants. In the UKBB, the minor allele frequency of the MYOC p.Gln368Ter variant was 1 in 786 individuals (0.13%). The odds ratio of p.Gln368Ter in patients with primary open-angle glaucoma (POAG) was 6.76 (95% CI, 4.05-11.29); glaucoma (POAG, self-reported glaucoma, and unspecified glaucoma), 4.40 (95% CI, 3.38-5.71); OHT, 3.56 (95% CI, 2.53-4.92); and OHT and glaucoma combined, 4.18 (95% CI, 3.05-5.67). The penetrance of the MYOC p.Gln368Ter variant was 7.6% in patients with glaucoma, 24.3% in patients with OHT, and 30.8% in patients with OHT and glaucoma combined. In the Australian registry studies, the odds of MYOC p.Gln368Ter variant were 12.16 (95% CI, 6.34-24.97) in patients with advanced glaucoma and 3.97 (95% CI, 1.55-9.73) in those with nonadvanced glaucoma; the penetrance of glaucoma was 56.1%, and penetrance in those considered to have glaucoma or be glaucoma suspects was 69.5%.

CONCLUSIONS AND RELEVANCE The MYOC p.Gln368Ter variant confers a very high-risk effect size for advanced glaucoma; the risk is lower in nonadvanced glaucoma and OHT. In the general population sample, approximately 50% of MYOC p.Gln368Ter carriers 65 years and older had glaucoma or OHT, with higher prevalence in the Australian registry studies.

Published online September 27, 2018.
Glaucoma is the leading cause of irreversible blindness globally. The most common forms of glaucoma are primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG). For the population older than 40 years, the worldwide age-standardized prevalence of glaucoma is 3.54%; for POAG and PACG, it is 3.05% and 0.50%, respectively.1 It is estimated there were 60.5 million patients with POAG and PACG worldwide in 2010, and that number will be 112 million by 2040.1,2 Elevated intraocular pressure (IOP) is the major modifiable risk factor for POAG. Progression of POAG is arrested or reduced if the IOP is lowered by 30% to 50% from baseline.3

Genetic factors play an important role in glaucoma.4-6 Having a first-degree relative with glaucoma raises the likelihood of developing glaucoma by 9.4-fold relative to the general population.7 A recent large-scale study estimated the heritability of glaucoma to be 70% using reconstructed family data.8 The myocilin gene (MYOC) at the GLC1A locus was the first gene discovered to be associated with POAG.9,10 Pathogenic variants in MYOC have been found in 2% to 4% of individuals with POAG.11,12 The exact pathogenic mechanisms by which disease-causing variants in MYOC might cause glaucoma have not been elucidated completely, but evidence supports a dominant-negative mechanism.13,14

The p.Gln368Ter variant (rs74315329) is the most common MYOC variant among populations of European ancestry.11,13,15 The association between p.Gln368Ter and POAG has an odds ratio (OR) greater than 10, with the p.Gln368Ter variant associated with younger age at onset and greater severity of IOP elevation.16,17 The estimated penetrance of p.Gln368Ter in glaucoma and ocular hypertension (OHT) has been inconsistent between family studies and general population-based studies.11,12,15,18-20 There are several potential explanations for this inconsistency. Estimates from family studies may be inflated because of ascertainment bias, aggregation of other genetic factors, and/or confounds by common environmental risk factors. Conversely, estimates from general population-based designs are likely to be low because of undersampling of cases (especially more severely affected cases) among volunteer-based studies.20 Additionally, for both family studies and general population-based studies, statistical power is typically low because of the relatively low numbers of p.Gln368Ter carriers.

In this study, we explore the penetrance and association of MYOC p.Gln368Ter variant with glaucoma and OHT in white European individuals enrolled in the UK Biobank (UKBB) study and compare the results with registry-based studies.

Methods

The UKBB project is a large-scale prospective cohort study of approximately 500 000 individuals across the United Kingdom, aged between 40 and 69 years at the time of recruitment (2006-2010). Detailed information on the UKBB study is available online (http://www.ukbiobank.ac.uk/resources/), and the genotype curation process is described in Bycroft et al.21
Among the 438 870 participants with genetic data, we removed participants who withdrew consent (n = 10 [<0.01%]). From the remaining 438 860 participants, individuals with glaucoma were identified via the following criteria: they (1) had an International Classification of Diseases, Ninth Revision (ICD-9) or Tenth Revision (ICD-10) diagnosis of primary open-angle glaucoma, other glaucoma, or glaucoma, unspecified; (2) reported glaucoma in a survey item inquiring about eye problems or disorders (UKBB data field 6148); or (3) reported glaucoma in a survey item on self-reported noncancer illness (UKBB data field 20002). Individuals with POAG were identified by an ICD-9 or ICD-10 diagnosis of POAG. Among participants with IOP measurements, those with IOPcc measurements greater than 21 mm Hg were defined as having OHT or glaucoma, as were those individuals identified as having glaucoma. The information for age at glaucoma onset was gathered from UKBB data fields 4689 and 20009; field 21022 was regarded as age at recruitment.

Finally, individuals were selected as healthy control participants for glaucoma, POAG, and OHT if they did not have other serious eye diseases (UKBB data field 6148; 26,576 individuals excluded) and (2) did not have other kinds of glaucoma diagnosed by ICD-9 or ICD-10 (diagnosed as a glaucoma suspect or diagnosed with PACG or secondary glaucoma; 947 individuals excluded). For control participants without POAG, 6886 individuals with other types of glaucoma were regarded as having not-available status. In total, 411,337 UKBB participants were included in this study. The flowchart illustrating selection criteria is shown in eFigure 2 in the Supplement.

In addition to examining population-based data, we considered participants from 2 registry-based studies: the Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG) and the Glaucoma Inheritance Study in Tasmania (GIST). Recruitment has been previously described. In brief, patients with glaucoma from Australia and New Zealand had been referred to the ANZRAG by their ophthalmologists. Participants in the GIST were recruited from surveys distributed to ophthalmology clinics and advertisements around Tasmania. Clinical information was collected by the patient’s treating ophthalmologist. Participants from ANZRAG and GIST were considered to have glaucoma if they had glaucomatous visual field defects on standard automated perimetry and neuroretinal rim thinning (cup-to-disc ratio [CDR] ≥0.7 or CDR asymmetry ≥0.2). Individuals considered to be glaucoma suspects had OHT defined by an IOP greater than 21 mm Hg or had preperimetric glaucoma based on glaucomatous appearance of the optic disc or thinning or the retinal nerve fiber layer with no glaucomatous field changes.

There were 2 arms to the ANZRAG and GIST component. First, there was a sequencing-based study within the ANZRAG and GIST data sets alone, to estimate the penetrance of p.Gln368Ter variants. Second, an array-based genome-wide association study allowed the estimation of the odds of glaucoma in a large sample of individuals with cases and control participants sourced from outside ANZRAG and GIST.

In the sequencing-based study, all participants with glaucoma and their relatives in the ANZRAG and GIST registries underwent Sanger sequencing for MYOC exon 3, as previously described. Participants who were found to be MYOC p.Gln368Ter carriers were considered Sanger validated, and age at diagnosis was ascertained.

In the array-based study, we selected a total of 3071 unrelated participants with glaucoma from the ANZRAG and GIST registries and 6750 unscreened control participants from the Brisbane Adolescent Twin Study, the Australian Cancer Study, a study of inflammatory bowel diseases, and a study of endometriosis. The samples were genotyped on Omni 1M (Illumina), OmniExpress (Illumina), or HumanCoreExome (Illumina) arrays; approximately two-thirds of cases were genotyped on HumanCoreExome arrays, with the remainder typed on arrays with higher single-nucleotide polymorphism density (Omni 1M and OmniExpress), with a similar proportion among the control participants. Genotype imputation was performed using Minima3 through the Michigan Imputation Server, with the Haplotype Reference Consortium release 1.1 as the reference panel.

We investigated the effect size of p.Gln368Ter for individuals with advanced glaucoma (n = 1753 of 3071 [57.1%]) and nonadvanced glaucoma (n = 1318 [42.9%]) separately. Individuals with advanced and nonadvanced glaucoma were defined as previously described.

Statistical Analysis

Descriptive statistics are presented as means (SDs) for continuous variables or as numbers (percentages) for categorical variables. Continuous variables were compared between groups using analysis of variance, whereas Pearson χ² or Fisher exact tests were used for categorical variables. We explored the prevalence of glaucoma and OHT in 4 age groups (younger than 50 years, 50-59 years, 60-65 years, and older than 65 years) of MYOC p.Gln368Ter carriers. We also investigated the cumulative risk of glaucoma by age 50 years, 60 years, and 65 years using a Cox model (adjusted for sex and the first 6 genetic principal components of the UKBB) or the Kaplan-Meier method (ANZRAG and GIST). The association between p.Gln368Ter dosage and disease status was estimated using logistic regression adjusted for sex, age, and the first 6 genetic principal components. To control bias from familial relationships in association analysis, we used a relationship-based pruning strategy in plink to exclude 1 member of each pair of samples if the genomic relatedness was greater than 0.2. We used the basic packages and survival package in analyses in R (version 3.4.1; http://www.r-project.org). We used 2-tailed P values and an α level of .05. Analysis was completed from September 2017 to July 2018.

Results

Table 1 shows the baseline characteristics of the 411,337 UKBB participants included in this study. Of these, 188,725 participants (45.9%) were male. The mean (SD) age of participants was 56.6 (8.0) years, with a mean (SD) IOPcc of 16.1 (3.5) mm Hg and a mean (SD) IOPg of 15.9 (3.6) mm Hg. We observed a trend that the mean level of IOP increased with age.
Among the 411,337 UKBB participants, 7,997 individuals with glaucoma (1.9%) were identified. A total of 1,111 individuals with POAG were identified by an ICD-9 or ICD-10 diagnosis of primary open-angle glaucoma. From 411,337 UKBB participants, it was estimated that 1,046 carried the p.Gln368Ter AG genotype. The minor allele frequency (MAF) of risk allele A of p.Gln368Ter was 1 of 786 participants (0.13%), and the observed MAFs were roughly the same across different age groups. As expected, given the frequency, no AA homozygotes were observed.

The MYOC p.Gln368Ter penetrance and its association with glaucoma and OHT are summarized in Table 2. The penetrance of p.Gln368Ter in glaucoma was estimated to be 7.6% (n = 79 of 1,046); in POAG, it was 1.6% (n = 16 of 1,046); in OHT, 24.3% (n = 52 of 214); and in OHT or glaucoma combined, it was estimated to be 30.8% (n = 66 of 214). The odds ratio of p.Gln368Ter in glaucoma was 4.40 (95% CI, 3.38-5.71); in POAG, it was 6.76 (95% CI, 4.05-11.3); in OHT, it was 3.56 (95% CI, 2.53-4.92); and in OHT and glaucoma combined, it was estimated to be 4.18 (95% CI, 3.05-5.77). For p.Gln368Ter carriers, their IOP was 2.04 (95% CI, 1.44-2.64) mm Hg higher than in individuals of GG genotype.

In the UKBB, the age-associated prevalence of glaucoma, POAG, OHT, and OHT or glaucoma is summarized in Table 3 and the Figure. In p.Gln368Ter carriers older than 65 years, the prevalence of glaucoma was 15.5% (n = 30); in POAG, it was 4.1% (n = 7); in OHT, 40.0% (n = 20); and in OHT and glaucoma combined, 48.0% (n = 24).

We gathered information on age at glaucoma onset for 4,915 individuals; the mean (SD) age at diagnosis was 53.5 (10.8) years. The cumulative risk of glaucoma at 50 years was 2.3% (95% CI, 1.3%-3.2%). At 60 years, it was 8.1% (95% CI, 6.0%-10.3%), and at 65 years, it was 15.6% (95% CI, 11.7%-19.3%; eTable 1 in the Supplement).

In the sequencing-based study, 174 participants in the ANZRAG and GIST registries were found to be Sanger-validated MYOC p.Gln368Ter carriers, including 164 with a known age at diagnosis. Among these 164 individuals (77 male and 87 female), 92 (56.1%) had glaucoma,24 22 (13.4%) were considered to be glaucoma suspects, and 50 (30.5%) were unaffected. The mean (SD) age at glaucoma diagnosis was 53.2 (12.9) years, and their mean (SD) IOP at diagnosis was 32.5 (9.5) mm Hg. The penetrance of p.Gln368Ter with respect to glaucoma was 56.1% (n = 92); for a wider definition, including both

---

**Table 1. Characteristics of 411,337 UK Biobank Study Participants**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Mean (SD)</th>
</tr>
</thead>
</table>
| Age, y          | 45.0 (2.7)  
| Age <50 y (n = 94,164) | 54.8 (2.9)  
| Age 50-59 y (n = 138,395) | 61.9 (1.4)  
| Age 60-65 y (n = 101,322) | 66.9 (1.5)  |
| Sex, No. (%)    |           |
| Male            | 42,529 (45.2)  
| Female          | 51,635 (54.8)  |
| Corneal-compensated intraocular pressure, mm Hg | 15.20 (3.2)  
| Goldmann-correlated intraocular pressure, mm Hg | 15.38 (3.4)  |

**Table 2. Disease Prevalence, Penetrance, and Risk Effect of Myocilin (MYOC) Gene p.Gln368Ter Variant in the UK Biobank**

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>No. (%)</th>
<th>Odds Ratio (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>1046 (0.3)</td>
<td>79 (7.6)</td>
<td>4.40 (3.38-5.7)</td>
</tr>
<tr>
<td>With intraocular pressure measurements</td>
<td>214 (0.3)</td>
<td>7918 (1.9)</td>
<td>NA</td>
</tr>
<tr>
<td>Glaucoma (n = 1046)</td>
<td>79 (7.6)</td>
<td>7918 (1.9)</td>
<td>4.40 (3.38-5.7)</td>
</tr>
<tr>
<td>Primary open-angle glaucoma (n = 1046)</td>
<td>16 (1.6)</td>
<td>1095 (0.3)</td>
<td>6.76 (4.05-11.3)</td>
</tr>
<tr>
<td>Ocular hypertension (n = 214)</td>
<td>52 (24.3)</td>
<td>6775 (8.0)</td>
<td>3.56 (2.53-4.9)</td>
</tr>
<tr>
<td>Ocular hypertension or glaucoma (n = 214)</td>
<td>66 (30.8)</td>
<td>8015 (9.5)</td>
<td>4.18 (3.05-5.7)</td>
</tr>
<tr>
<td>Intraocular pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corneal-compensated intraocular pressure, mean (SD), mm Hg</td>
<td>18.10 (4.5)</td>
<td>16.06 (3.5)</td>
<td>NA</td>
</tr>
<tr>
<td>Goldmann-correlated intraocular pressure, mean (SD), mm Hg</td>
<td>17.74 (4.3)</td>
<td>15.92 (3.6)</td>
<td>NA</td>
</tr>
</tbody>
</table>
Table 3. Age-Related Prevalence of Glaucoma and Ocular Hypertension in the UK Biobank*

<table>
<thead>
<tr>
<th>Age Group, y</th>
<th>Glaucoma</th>
<th>Ocular Hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>rs74315329 (AG)</td>
<td>rs74315329 (GG)</td>
</tr>
<tr>
<td>&lt;50</td>
<td>3 (1.3)</td>
<td>469 (0.5)</td>
</tr>
<tr>
<td>50-59</td>
<td>19 (5.2)</td>
<td>1817 (1.3)</td>
</tr>
<tr>
<td>60-65</td>
<td>27 (10.8)</td>
<td>2555 (2.5)</td>
</tr>
<tr>
<td>&gt;65</td>
<td>30 (15.5)</td>
<td>3077 (4.0)</td>
</tr>
</tbody>
</table>

Primary open-angle glaucoma

<table>
<thead>
<tr>
<th>Age Group, y</th>
<th>Glaucoma</th>
<th>Ocular Hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>rs74315329 (AG)</td>
<td>rs74315329 (GG)</td>
</tr>
<tr>
<td>&lt;50</td>
<td>1 (0.4)</td>
<td>36 (0.0)</td>
</tr>
<tr>
<td>50-59</td>
<td>3 (0.9)</td>
<td>216 (0.2)</td>
</tr>
<tr>
<td>60-65</td>
<td>5 (2.2)</td>
<td>326 (0.3)</td>
</tr>
<tr>
<td>&gt;65</td>
<td>7 (4.1)</td>
<td>517 (0.7)</td>
</tr>
</tbody>
</table>

Ocular hypertension

<table>
<thead>
<tr>
<th>Age Group, y</th>
<th>Glaucoma</th>
<th>Ocular Hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>rs74315329 (AG)</td>
<td>rs74315329 (GG)</td>
</tr>
<tr>
<td>&lt;50</td>
<td>9 (22.0)</td>
<td>715 (4.0)</td>
</tr>
<tr>
<td>50-59</td>
<td>12 (15.6)</td>
<td>1730 (6.4)</td>
</tr>
<tr>
<td>60-65</td>
<td>11 (23.9)</td>
<td>2172 (9.8)</td>
</tr>
<tr>
<td>&gt;65</td>
<td>20 (40.0)</td>
<td>2158 (12.7)</td>
</tr>
</tbody>
</table>


df *Approximately 5% of the individuals are removed because of relatedness prior to determination of significance. P values are from χ2 test or Fisher exact test comparing disease prevalence based on p.Gln368Ter genotypes in different age groups.

b Number of cases (prevalence).

Figure. Age-Associated Prevalence of Glaucoma, Suspected Glaucoma, and Ocular Hypertension in p.Gln368Ter Risk Allele Carriers

Table 4. Penetrance of p.Gln368Ter in the Australian and New Zealand Registry of Advanced Glaucoma and the GIST in Tasmania Registry-Based Studies

<table>
<thead>
<tr>
<th>Patient Status</th>
<th>rs74315329 (AG), No. (%)</th>
<th>Age at Last Examination, Mean (SD), y</th>
<th>Max Recorded IOP, Mean (SD), mm Hg</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with glaucoma</td>
<td>No</td>
<td>72 (43.9)</td>
<td>48.11 (16.7)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>92 (56.1)</td>
<td>69.13 (12.7)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

Patients with glaucoma and patients considered glaucoma suspects

<table>
<thead>
<tr>
<th>Patient Status</th>
<th>rs74315329 (AG), No. (%)</th>
<th>Age at Last Examination, Mean (SD), y</th>
<th>Max Recorded IOP, Mean (SD), mm Hg</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>50 (30.5)</td>
<td>42.50 (16.3)</td>
<td>&lt;.001</td>
<td>16.48 (2.87)</td>
</tr>
<tr>
<td>Yes</td>
<td>114 (69.5)</td>
<td>67.14 (13.1)</td>
<td>&lt;.001</td>
<td>30.01 (9.43)</td>
</tr>
</tbody>
</table>

To our knowledge, this is the largest study to examine the penetrance and association of the MYOC p.Gln368Ter carriers with glaucoma and OHT in a cohort of individuals of European ancestry and compare it with data from 2 large registry-based studies. We found that p.Gln368Ter was robustly associated with glaucoma, POAG, and OHT and that its penetrance increased with age.

The p.Gln368Ter variant was well imputed (with an imputation quality score of 93.8%), and the MAF was 0.13% in the UKBB data. In this study, the MAF was similar to those reported from exome sequencing databases (ie, 192 of 126 640 [0.15%]) in non-Finnish European individuals in the Genome Aggregation Database (http://gnomad.broadinstitute.org/) but much higher than that recently reported in the TwinsUK cohort (MAF, 8 of 12 184 [0.07%]).20 The lower MAF seen in the UKBB data is likely due to ascertainment bias toward healthy individuals.

In the UKBB study, individuals with POAG or glaucoma were identified by ICD-9 or ICD-10 diagnosis or self-reported questionnaires; the prevalence of POAG was estimated at patients with glaucoma and patients who were glaucoma suspects, the penetrance was 69.5% (n = 114; Table 4).

The Figure and eTable 2 in the Supplement present the age-associated prevalence of glaucoma and suspected glaucoma among p.Gln368Ter carriers in the ANZRAG and GIST registry-based studies. The cumulative risk of glaucoma in the UKBB study, individuals with POAG or glaucoma were 12.2 (95% CI, 6.3-25.0), and for those with nonadvanced glaucoma, they were 3.97 (95% CI, 1.6-9.8).
Myocilin Gene Gln368Ter Variant Penetration and Association With Glaucoma in Population-Based and Registry-Based Studies

Original Investigation Research

JAMA Ophthalmology January 2019 Volume 137, Number 1

© 2018 American Medical Association. All rights reserved.

0.27%, and the prevalence of glaucoma was estimated at 1.94%. A previous study estimated the prevalence in Europe of POAG at 2.51% and glaucoma at 2.93%. Previous studies also showed that 50% of glaucoma cases are undiagnosed. Because of the lack of a comprehensive eye examination in the UKBB, the proportion of individuals with glaucoma or POAG found here was lower than expected. However, IOP is a key risk factor for POAG, and the main mechanism of p.Gln368Ter is via elevation of IOP. The penetrance and risk effect of p.Gln368Ter in OHT serves as a proxy for POAG. The prevalence of OHT (defined as IOPcc >21 mm Hg) reported in this study was 8.08%, which is similar to an earlier study.

Family studies have shown that p.Gln368Ter had a high penetrance in POAG and OHT. For instance, Craig et al reported the age-related penetrance of p.Gln368Ter for OHT or POAG as 28 of 39 individuals (72%) at age 40 years and 14 of 17 individuals (82%) at age 65 years. Another study by Allingham et al observed that 9 of 9 people (100%) with the p.Gln368Ter variant had elevated IOP, and 7 of 9 individuals (78%) had POAG by age 70 years. The current analysis of ANZRAG and GIST registry data indicated that the cumulative risk at 65 years old was 87.1% for glaucoma and 96.0% for a combination of glaucoma and suspected glaucoma, which was consistent with findings from previous family-based studies.

From their population-based study, Nag et al reported that the penetrance of p.Gln368Ter in relation to OHT was 1 of 8 people (12.5%) in the TwinsUK study and 6 of 31 (19.4%) in the Rotterdam Study. The penetrance of p.Gln368Ter for POAG was 1 of 8 (12.5%) in the TwinsUK study and 3 of 31 (9.7%) in the Rotterdam Study. For OHT, our study showed that the penetrance of p.Gln368Ter (n = 52 of 214 [24.3%]) was lower than in the previous family studies but higher than in the population-based study.

With approximately 100,000 participants with IOP measurements, our study provided a more robust estimation of p.Gln368Ter penetrance in OHT in population-based studies. However, the number of individuals with POAG was much lower than expected, given the typical prevalence of POAG in Europe (2.51%). Hence, the true penetrance of p.Gln368Ter in POAG is likely to be larger than estimated in the UKBB samples in this analysis. This again may reflect the bias of a volunteer-based study design.

We also proposed a method to calculate the penetrance of p.Gln368Ter based on its odds ratio, MAF, and disease prevalence (eMethods in the Supplement). According to the proposed method, if the prevalence of glaucoma was 2.93% and that of POAG was 2.51% in populations older than 40 years, then using the odds ratios and MAF of p.Gln368Ter from the UKBB, the estimated overall penetrance of p.Gln368Ter for glaucoma was derived to be 10.7% and that of POAG was derived to be 15.1%.

The penetrance of p.Gln368Ter with respect to OHT and glaucoma combined is a more comprehensive indicator. This study showed that in p.Gln368Ter carriers, the cumulative risk of OHT or glaucoma was 38.69% at age 65 years in the population-based study and 95.96% in glaucoma-based registries; p.Gln368Ter genotyping has great potential for early identification of individuals at risk for developing these eye diseases.

The penetrance of p.Gln368Ter with respect to glaucoma in the UKBB data was lower than in the family studies. There are several potential reasons for this. On the one hand, estimates from family studies may have been inflated by ascertainment bias. On the other hand, the penetrance in general population-based studies may be underestimated because of undersampling of affected individuals. Furthermore, it remains possible that aggregated genetic and environmental risk factors in family studies may have led to increased penetrance in p.Gln368Ter carriers. Recruitment based on families with multiple affected individuals is likely to lead to an increase in the number of common variants of individually small effect (polygenes) in a family, potentially increasing the penetrance of variants such as p.Gln368Ter. This supports the use of cascade testing for close relatives who share the same genetic background.

Limitations
This study has some limitations. The genotypes of p.Gln368Ter in the UKBB study are based on best-guess imputed genotypes. Reassuringly, our previous study presented evidence that the p.Gln368Ter variant could be imputed with high accuracy. Thus, the imputed genotype is unlikely to make a meaningful difference in our results.

Another limitation of the UKBB study is that some individuals with glaucoma were defined by self-reported questionnaires, which could lead to recall bias. However, our study is one of the largest studies to investigate the penetrance and risk effect of p.Gln368Ter in OHT, which could serve as a proxy for glaucoma or POAG. Furthermore, individuals with glaucoma who also have other eye disorders may be less likely to participate the UKBB project, compared with healthy individuals, which could lead to a lower estimated penetrance of p.Gln368Ter in glaucoma. Moreover, in the ANZRAG and GIST registries, the controls were genotyped on different platforms. As a sensitivity analysis, we substituted the Australian control participants for controls from the UKBB data; our results were essentially unchanged.

Finally, some individuals with high IOP present in the UKBB cohort may be taking medications or have undergone ophthalmic surgery to reduce their IOP levels. In our sensitivity analysis to adjust for the change in IOP postmedication, when we added 25% to the measured IOP levels for individuals taking IOP-lowering medications, the resultant odds ratios and penetrance with respect to OHT increased only slightly.

Conclusions
Our study suggests that the MYOC p.Gln368Ter variant has a high penetrance in OHT and glaucoma. Genetic testing for p.Gln368Ter could help identify individuals who at greater risk of developing glaucoma and direct them to early screening and appropriate management.
Author Contributions: Statistical Genetics, QIMR Berghof Medical Research Institute, Brisbane, Australia (Han, Ong, An, Gharahkhani, MacGregor); School of Medicine, University of Queensland, St Lucia, Brisbane, Australia (Han, Ong); Department of Ophthalmology, Flinders University, Flinders Medical Centre, Adelaide, Australia (Souzeau, Siggs, Burdon, Mills, Landers, Craig); Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia (Burdon, Mackey, Hewitt); Eye Department, Greenlane Clinical Centre, Auckland District Health Board, Auckland, New Zealand (Best); Discipline of Ophthalmology, Sydney Eye Hospital, University of Sydney, Sydney, Australia (Goldberg, Healey, Graham); Centre for Vision Research, Westmead Institute for Medical Research, University of Sydney, Sydney, Australia (Healey, White); Ophthalmology and Vision Science, Faculty of Medicine and Human Sciences, Macquarie University, Australia (Graham); Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Australia (Ruddie, Hewitt); Ophthalmology, University of Melbourne, Department of Surgery, Melbourne, Australia (Ruddie); Department of Ophthalmology, Royal Children’s Hospital, Melbourne, Australia (Ruddie); South Australian Institute of Ophthalmology, Royal Adelaide Hospital, University of Adelaide, Adelaide, Australia (Galanopoulos, Casson); Centre for Ophthalmology and Visual Sciences, Lions Eye Institute, University of Western Australia, Perth, Australia (Mackley).

Author Contributions: Dr MacGregor had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Mr Han and Dr Souzeau contributed equally.

Concept and design: Han, Souzeau, Mackey, Hewitt, Craig, MacGregor.

Acquisition, analysis, or interpretation of data: Han, Souzeau, Ong, Siggs, Burdon, Best, Goldberg, Healey, Graham, Ruddle, Mills, Landers, Galanopoulos, White, Casson, Hewitt, Gharahkhani, MacGregor.

Drafting of the manuscript: Han, Souzeau, Ong, Gharahkhani, MacGregor.

Critical revision of the manuscript for important intellectual content: Han, Ong, Siggs, Burdon, Best, Goldberg, Healey, Graham, Ruddle, Mills, Landers, Galanopoulos, White, Casson, Mackey, Hewitt, Gharahkhani, Craig, MacGregor.

Statistical analysis: Han, Souzeau, Ong, An, Siggs, Gharahkhani, MacGregor.

Obtained funding: Burdon, Healey, Mackey, Hewitt, Craig, MacGregor.

Administrative, technical, or material support: An, Healey, Landers, Galanopoulos, Casson, Mackey, Hewitt.

Supervision: Burdon, Hewitt, Gharahkhani, Craig, MacGregor.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Goldberg reports serving on advisory board for Novartis and Allergan, Mundipharma, and Pfizer, and receiving speakers’ fees from Mundipharma and Pfizer. No other disclosures were reported.

Funding/Support: This work was supported by the National Health and Medical Research Council of Australia (grants 1107098, 1116360, 1116495, and 1023991), the Ophthalmic Research Institute of Australia, and the BrightFocus Foundation. Dr Han is supported by the University of Queensland Research Training Scholarship. Mr Ong is supported by scholarship from the University of Queensland and QIMR Berghof Medical Research Institute. Drs Burdon and Craig are supported by National Health and Medical Research Council Fellowships. Dr MacGregor is supported by an Australian Research Council Future Fellowship.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We gratefully thank all the participants or volunteers who participated in the studies. We acknowledge David Whitman, PhD, MD, Graham Radford-Smith, MD, and Nick Martin, PhD, QIMR Berghof Medical Research Institute, and Grant Montgomery, PhD, Institute for Molecular Bioscience, University of Queensland, for providing access to control samples. They were not financed financially for their contributions to this work.

Additional Information: This study was conducted using the UK Biobank Resource (application 25331).

REFERENCES
Penetration of Myocilin Mutations—Who Gets Glaucoma?

John H. Fingert, MD, PhD

Mutations in the myocilin (MYOC) gene were discovered as a cause of primary open-angle glaucoma (POAG) in 1997.1 Twenty-one years later, mutations in MYOC remain the most common molecularly defined cause of glaucoma and are responsible for 3% to 4% of adult-onset POAG cases.2 Glaucoma associated with MYOC is transmitted with autosomal dominant inheritance3; offspring from parents with glaucoma caused by a MYOC mutation have a 50% chance of inheriting the mutation and increased risk for glaucoma. The most common glaucoma-associated MYOC mutation is a nonsense mutation, Gln368Stop, that produces truncated MYOC protein that is missing its last quarter.2 This mutation has been detected in 1.6% of patients with POAG in large case-control studies and is responsible for more glaucoma than any other known mutation.4 In their article in JAMA Ophthalmology, Han et al5 evaluated very large study populations to investigate just how high the risk for glaucoma is for those with this MYOC mutation.

Not all of those with a Gln368Stop mutation have glaucoma. Some do not have glaucoma at the time of an initial examination but may develop disease later in life, while others will never develop glaucoma despite having the mutation. The proportion of people with a mutation (eg, Gln368Stop) that have an associated disease (eg, POAG and/or ocular hypertension) is referred to as the penetrance of that mutation. Determining the penetrance of a disease-associated mutation is of paramount importance for accurate diagnostic and prognostic counseling. Moreover, new potential drug therapies and genome-editing therapies are being developed for MYOC-associated glaucoma and their ultimate usefulness may be influenced by estimates of the penetrance of MYOC mutations.

Prior studies have estimated the penetrance of the Gln368Stop mutation. Penetration was first calculated with studies6,7 of large pedigrees of patients with glaucoma caused by the Gln368Stop mutation. These pedigree-based studies8,9 have suggested that the Gln368Stop mutation has a high penetrance that is age dependent. Among these families, the proportion of mutation carriers with glaucoma was found to increase to 73% to 100% by the seventh decade of life.

While pedigree studies suggested that most Gln368Stop mutation carriers ultimately develop disease, population-based studies have indicated that this mutation may have a lower penetrance in other patient cohorts. In 2016, Nag et al10...